038290.Kq
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
The company's capital structure shows a debt-to-equity ratio of 0.65, indicating a moderate level of leverage. However, the liquidity position is constrained, with a current ratio of 0.82, suggesting that the company may struggle to meet short-term obligations without additional financing. The free cash flow is negative at -22,798,801,230 KRW, which is a concern for maintaining operations and funding growth initiatives.
Profitability metrics reveal a return on equity (ROE) of 1.29% and a return on assets (ROA) of 0.58%, both of which are below the industry average for biotechnology and medical research firms. The net income of 2,030,024,760 KRW is modest given the company's asset base of 351,624,587,020 KRW, indicating that the company is not generating strong returns relative to its size.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic diversification provided in the available data. This lack of diversification could expose the company to regional economic downturns or regulatory changes that affect the healthcare diagnostics market.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating income is negative at -544,104,940 KRW, which suggests that the company is not yet profitable from its core operations. The capital expenditure of -36,041,250,200 KRW indicates significant investment in infrastructure or expansion, which may be a precursor to future growth.
The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted figures. However, the negative free cash flow and high capital expenditures may necessitate future equity or debt financing, which could lead to dilution.
Recent events, as reflected in the financial data, include a negative operating income and a negative free cash flow, which may signal operational challenges. The company's EPS estimate of 1,028 KRW is significantly higher than the last actual EPS of 187 KRW, suggesting that analysts expect a substantial improvement in earnings performance.
- The company has a moderate debt-to-equity ratio but faces liquidity constraints with a current ratio below 1.
- Profitability metrics are weak, with ROE and ROA below industry averages.
- The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Analysts expect a significant improvement in earnings, but the company is currently unprofitable from operations.
- The company is investing heavily in capital expenditures, which may support future growth but is currently straining cash flow.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1 028,00 |
| Revenue | —no estimate | —no estimate | 241,1B KRW |
| Operating income | —no estimate | —no estimate | 12,4B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 038290.KQ Market data — financials · 2026-05-26
- Macrogen Inc Market data — analyst estimates · 2026-05-26